- Home
- MOBX vs DRRX Comparison
MOBX vs DRRX Comparison
Compare MOBX & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- DRRX
- Stock Information
- Founded
- MOBX 2020
- DRRX 1998
- Country
- MOBX United States
- DRRX United States
- Employees
- MOBX N/A
- DRRX N/A
- Industry
- MOBX
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- DRRX Health Care
- Exchange
- MOBX Nasdaq
- DRRX Nasdaq
- Market Cap
- MOBX 57.1M
- DRRX 59.3M
- IPO Year
- MOBX N/A
- DRRX 2000
- Fundamental
- Price
- MOBX $0.93
- DRRX $1.91
- Analyst Decision
- MOBX
- DRRX Hold
- Analyst Count
- MOBX 0
- DRRX 1
- Target Price
- MOBX N/A
- DRRX N/A
- AVG Volume (30 Days)
- MOBX 1.7M
- DRRX 699.4K
- Earning Date
- MOBX 08-13-2025
- DRRX 11-12-2025
- Dividend Yield
- MOBX N/A
- DRRX N/A
- EPS Growth
- MOBX N/A
- DRRX N/A
- EPS
- MOBX N/A
- DRRX N/A
- Revenue
- MOBX $10,984,000.00
- DRRX $1,657,000.00
- Revenue This Year
- MOBX N/A
- DRRX N/A
- Revenue Next Year
- MOBX N/A
- DRRX $673.00
- P/E Ratio
- MOBX N/A
- DRRX N/A
- Revenue Growth
- MOBX 180.13
- DRRX N/A
- 52 Week Low
- MOBX $0.55
- DRRX $0.48
- 52 Week High
- MOBX $2.47
- DRRX $2.64
- Technical
- Relative Strength Index (RSI)
- MOBX 45.49
- DRRX 67.35
- Support Level
- MOBX $1.00
- DRRX $1.86
- Resistance Level
- MOBX $1.19
- DRRX $1.97
- Average True Range (ATR)
- MOBX 0.16
- DRRX 0.03
- MACD
- MOBX -0.01
- DRRX -0.04
- Stochastic Oscillator
- MOBX 14.17
- DRRX 14.29
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.